Ares Life Sciences, a venture capital firm specializing in expansion and late-stage investments, and Waypoint, an investment company, completed the acquisition of Stallergenes Greer, a global biopharmaceutical company specializing in the diagnosis and treatment of respiratory allergies through immunotherapy, for $134m. "The Special Committee has given careful consideration to the proposal by Waypoint and believes that the value proposed recognizes the future potential of the business and the improved prospects of Stallergenes Greer following recent efforts by management. The proposal also represents an attractive cash premium to the current share price as well as a source of liquidity for Shareholders. As majority shareholder, Waypoint has been consistently and demonstrably supportive of Stallergenes Greer. We have confidence that with 100%. ownership of Stallergenes Greer, Waypoint will develop the business into a successful future to the benefit of patients, employees and other stakeholders," Elmar Schnee, Stallergenes Greer the Chairman.